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Background and aims: Antimitochondrialantibodies(AMA)whichrecognizepyruvateacetyltransferase
(PDC-E2) represent a highly diagnostic feature of primary biliary cirrhosis (PBC). The analysis of
immunoﬂuorescence(IF)-AMA-positivesera inPBCpatientsindicatesaconformationalepitope located
within the lipoyl binding domain of bovine branched-chain acyltransferase (BCKADC-E2) alone or
in combination with AMA directed against PDC-E2 the signiﬁcance of which is presently unclear.
In the present study, immunoreactivities and disease associations of AMA against BCKADC-E2 were
analyzed. B-cell autoepitopes on BCKADC-E2 were mapped by immunoprecipitation assay.
Methods: Sera of 96 IF-AMA-positive patients with serological evidence of anti-BCKADC-E2 alone
(n ¼ 26), anti-PDC-E2 alone (n ¼ 15), and both anti-BCKADC-E2 and anti-PDC-E2 (n ¼ 55) were
analyzedbyWesternblotandELISAinadditiontoananalysisofBcellautoepitopesonBCKADC-E2by
immunoprecipitation using in vitro translated, unmodiﬁed human proteins. Ninety-four patients without
IF-AMA[blooddonors(n ¼ 30),rheumatoidarthritis(n ¼ 40),autoimmunehepatitis(AIH)(n ¼ 10)and
primary sclerosing cholangitis (PSC) (n ¼ 14] served as controls.
Results: Eighty of 81 (99%) sera positive for BCKADC-E2 recognized the full length, mature protein,
while only 2/10 AIH sera and none of the other controls showed reactivity. Of the 68 PBC sera 58 (85%)
recognized the N-terminus consisting of aa 1–144 representing the lipoyl domain. Surprisingly,
C-terminalsequences(aa 143–421)wererecognizedby46outof68sera(68%).ThreePBCserareacted
withtheC-terminusonly.Only1/7serumfrompatientswithan”overlapsyndromeofPBCandAIH”was
reactive with C-terminal sequences.
Conclusions: Our analysis of BCKADC-E2-positive PBC sera identiﬁed a novel B cell epitope on the
C-terminal part of the human protein. Our data indicate that a distinct subset of AMA recognize
sequence(s) on BCKADC-E2 which located outside of the lipoyl binding domain. The absence of
immunoreactivity against C-terminal sequences may serve as a marker differentiating patients with PBC
and overlap syndrome of PBC with AIH.
Keywords: Lipoyl domain; Epitope; Primary biliary cirrhosis; Antimitochondrial antibodies;
Branched-chain acyltransferase
Abbreviations: PBC, primary biliary cirrhosis; AMA, antimitochondrial antibodies; BCKADC-E2,
branched-chain acyltransferase; RLA, radioligand assay; PDC-E2, dihydrolipoamide acetyltransferase;
pCITE, plasmid vector with cap-independent translation enhancer sequence; cpm, counts per minute;
SDS-PAGE, sodium dodecyl sulfate polyacrylamide electrophoresis; AIH, autoimmune hepatitis; PSC,
primary sclerosing cholangitis; OLT, orthotopic liver transplantation
INTRODUCTION
The loss of B-celltolerance toward mitochondrial antigens
is a highly speciﬁc serological marker of primary biliary
cirrhosis (PBC) present at high titers in patients with PBC
(Baum, 1994; Berg and Klein, 1995). PBC is a chronic
cholestatic liver disease predominantly affecting middle-
aged women. It is characterized by the progressive
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100mm diameter and by portal inﬂammation ultimately
leading to biliary cirrhosis in a variable course of time.
An early diagnosis is required for therapeutic planning
and is signiﬁcantly inﬂuenced by the speciﬁc detection
of antimitochondrial antibodies (AMA) in serum
(Walker et al., 1965; Kaplan, 1996; Kim et al., 2000).
The analysis of AMA autoepitopes has led to the
identiﬁcation of a dominant epitope of the major auto-
antigen for AMA in PBC, the dihydrolipoamide
acetyltransferase of the pyruvate dehydrogenase complex
(PDC-E2), which is located within a 20 amino acid
hydrophilic segment (residues 167–186) around the lipoic
acid bound lysine of the inner lipoyl domain (Gershwin
et al., 1987; Coppel et al., 1988; van de Water et al., 1988;
Surh et al., 1990). This short peptide, although central
to the dominant epitope, is a weak antigen. The entire
inner lipoyl binding domain (residues 128–221) was
demonstrated to be necessary for full immunoreactivity
(Burroughs et al., 1992). Use of a cDNA clone isolated
from a human fetal liver library showed that a second
mitochondrial enzyme of 52kDa, the branched-chain
acyltransferase (BCKADC-E2) was also recognized
by AMA from a large number of PBC patients
(Surh et al., 1989). Up to 71% of PBC sera were reported
to recognize BCKADC-E2, of which 5–20% of sera
exclusively reacted with this autoantigen without the
presence of anti PDC-E2 antibodies (Fregeau et al., 1989;
James et al., 1989; Iwayama et al., 1992; Leung et al.,
1995). AMA against BCKADC-E2 were found to inhibit
the function of the branched-chain a-keto-acid dehydro-
genase enzyme complex (Fregeau et al., 1989).
Available data on B cell autoepitope(s) on the
BCKADC-E2 molecule were generated using expression
clones of bovine BCKADC-E2 cDNA (Grifﬁn et al.,
1990). Leung and colleagues evaluated PBC sera (n ¼ 9)
and reported that the major epitope resided on the lipoyl
binding domain. However, only the full-length clone
encoding the mature protein was sufﬁcient to remove
all detectable reactivity with BCKADC-E2. Recently,
published data suggest that BCKADC-E2 may have
further autoepitopes other than the lipoyl domain itself
(Migliaccio et al., 1998).
In our analysis, we have used a full-length human
cDNA encoding BCKADC-E2 (Lau et al., 1992) and
mapped epitope(s) by a radioligand assay (RLA) in order
to gain more insight into the nature of the B-cell immune
response to BCKADC-E2 and to evaluate the clinical
signiﬁcance of BCKADC-E2 autoantibodies in PBC.
PATIENTS AND METHODS
Serum Samples and Patients
Ninety-six sera with a positive immunoﬂuorescence AMA
test (IF-AMA) on rat tissue sections (kidney, liver and
stomach) or on HEp2 cells at a titer of $1:80 were
selected for further autoantibody determinations. Twenty-
seven sera were obtained from Hungarian patients
and 69 sera were selected among sera evaluated
in the Autoantibody Laboratory of the Department of
Gastroenterology and Hepatology (Medical School
of Hannover, Germany). IF-AMA-positive sera were
further evaluated by Western blot (WB) and ELISA. Sera
giving the classical IF-AMA pattern that were positive for
BCKADC-E2 reactivity detected both by WB and ELISA
were considered as BCKADC-E2 positive and were
selected for epitope mapping. Epitope mapping experi-
ments were performed under blinded conditions, because
at the time of autoantibody determinations clinical,
biochemical and histological data were not available for
investigators in order to exclude bias in the sera analysis.
Controls included 94 sera without IF-AMA obtained
from healthy blood donors (n ¼ 30), patients with
rheumatoid arthritis but without any evidence of liver
disease (n ¼ 40), autoimmune hepatitis (AIH) (n ¼ 10)
and primary sclerosing cholangitis (PSC) (n ¼ 14).
Rheumatoid arthritis, AIH and PSC were diagnosed
according to international criteria (Wiesner and La Russo,
1980; Arnett et al., 1988; Johnson and McFarlane, 1992).
All sera were stored at 2208C until further analysis.
Informed consent was obtained from all patients, and the
study protocol was approved by the local ethics
committees.
“Deﬁnite” PBC: Three diagnostic criteria were
required for deﬁnite PBC: (1) a positive IF-AMA test
result ($1 in 80 on Hep2 cells and/or rat tissue slides);
(2) pathological serum liver function test(s) [(alkaline
phosphatase (ALP) and/or gamma glutamyl transferase
(GGT)]; (3) a diagnostic or compatible liver histology
(Long et al., 1977).
“Probable” PBC: PBC was deﬁned as probable if two
of the previous criteria were fulﬁlled.
“PBC-AIH overlap” syndrome: An “overlap”
syndrome of PBC and AIH was deﬁned by the
simultaneously association of PBC and AIH. The ﬁrst
three criteria for PBC were as above described and the
fourth criterion was a serum immunoglobulin M (IgM)
level at least 1.5 times above the upper limit of normal
value. Criteria for AIH were: (1) serum alanine (ALT) or
aspartate (AST) aminotransferase levels at least three
times the upper limit of normal; (2) serum immuno-
globulin G (IgG) levels at least two times the upper limit
of normal values; (3) positive test result(s) for smooth
muscle antibodies (SMA) (IF $1:80) or anti-nuclear
antibodies (ANA) (IF $1:80); (4) liver histology showing
interface hepatitis. Deﬁnite diagnosis of each condition
required the presence of at least three of the four criteria.
In each patient, absence of biliary obstruction was
assessed by ultrasound. None of the patients had a history
of excessive alcohol consumption (.30g/d), there was no
evidence of exposure to hepato- or cholangiotoxic drugs.
Serological tests for hepatitis B virus infection were
negative. Two patients were found to have antibodies
against the hepatitis C virus (anti-HCV) and active viral
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disease after receiving interferon alfa2a and met all
criteria necessary for “deﬁnite” PBC. The other had
laboratoryevidence of cholestasis and histology consistent
with PBC.
Indirect Immunoﬂuorescence Analysis
Sera were diluted 1:40, 1:80 and 1:160 in phosphate
buffered saline without magnesium and calcium (PBS).
Frozen cryosections of 4mm-tissue from rat liver, kidney
and stomach and HEp2 cell monolayers on glass slides
(Labor Diagnostika, Heiden, Germany) were incubated
with diluted sera for 30min at room temperature.
Following two washing steps with PBS, the slides were
incubated in a humidiﬁed, dark chamber for 30min with
ﬂuorescein isothiocyanate-conjugated afﬁnity puriﬁed
goat anti-human polyclonal (IgG, IgM, IgA) antiserum
(Dianova, Hamburg, Germany). Following two washing
steps with PBS, tissue slices were analyzed using an
Olympus IMT 2 immunoﬂuorescence microscope (Tokyo,
Japan). Sera were considered AMA positive with a titer
higher that 40.
Western Blot Analysis
All sera were analyzed by (Western) immunoblotting
(WB). Mitochondrial fractions of rat liver cell homogen-
ate were obtained by differential centrifugation.
The mitochondrial fraction was subjected to electro-
phoresis on a sodium-dodecyl sulfate-polyacrylamide
gradient (5–20%) gel-electrophoresis (SDS-PAGE) and
subsequently transferred to nitrocellulose ﬁlter (Trans-
Blot, Bio-Rad Labs, Richmond, CA). The blot was stored
at 2208 C. The strips were rehydrated in PBS and blocked
for 20min with PBS containing 2% (v/w) milk powder.
Serum samples were diluted 1:100 in PBS. After removal
of the blocking buffer, membrane strips were incubated in
the diluted serum for 2h at room temperature. During the
incubation step all speciﬁcally bound antibody was
detected by alkaline phosphatase-conjugated afﬁnity
puriﬁed goat anti-human IgA þ IgG þ IgM (H þ L)
antibody (Jackson ImmunoResearch Labs, West Grove,
PA). After three washings with Tris buffered saline
including Tween 20 (0.1%) (TBST) to remove
excess enzyme label, speciﬁcally bound antibody was
detected by the use of a chromogenic reaction with
50bromo-40chloro-30indolyl-phosphate-toluidine and
40nitro-tetrazolium-chloride Blue (Sigma GmbH,
Deisenhofen, Germany) for 15min.
Competitive ELISA
A competitive ELISAwas used to detect autoantibodies to
BCKADC-E2. Brieﬂy, the wells of a 96-round-bottom-
well polystyrane plate (Dynatech, Germany) were coated
overnight at 48C with 50ml of puriﬁed IgG BCKADC-E2
antibodies (20mg protein/ml in PBS) obtained from sera
monospeciﬁc to anti-BCKADC-E2 as described
previously (Long et al., 1977). After removal of the
excess autoantibody and washing with PBS with 0.1%
Tween 20 (PBS-Tween 20), the free binding sites on the
plates were blocked by addition of 1% bovine serum
albumin (BSA) in PBS (BSA-PBS) and incubated for 24h.
After washing the wells with PBS-Tween 20, 50mlo f
differentially centrifuges mitochondrial protein from rat
liver cell homogenate (100mg/ml in PBS) was added and
incubated for 1h at room temperature on a microplate
rotating platform. Plates were washed twice with
PBS-Tween 20 before 50ml of 1:10 diluted serum
samples in PBS with 10mM EDTA were added and
incubated for 1h at room temperature on a rotating
platform. In each assay, a strong positive and several
negative sera as controls were included and serum samples
were measured in duplicate. After washing three times
with PBS-Tween 20, 50ml of the biotin-labeled
BCKADC-E2 antibodies (diluted to 1:100 in BSA-PBS)
were added to each well. Incubation for 1h on a
microplate rotating platform was followed by three
washing steps with PBS-Tween 20. Afterwards, 50mlo f
avidin-horseradish peroxidase conjugate (diluted to
1:1500 in BSA-PBS) (Dako, Danemark) were added and
incubated for 1h. After washing the plates, 50mlo f
substrate solution (2,20 azinobis-3-ethylbenzthiazolin
sulfonic acid and sodium perborate in citrate buffer)
were added. The plates were incubated at room
temperature until a dark-color reaction developed in
control sera without anti-BCKADC-E2 antibodies.
The reaction was stopped by adding 100ml 1M citric
acid. The optical density was read at 405nm. Results were
expressed as percentage of inhibition of biotinylated
reference antibodies to BCKADC-E2. Samples with
values higher than the mean value of healthy controls
plus 3SD were considered positive. The cut-off for
positivity was 20% inhibition of binding.
Complementary DNA Clones
The complete cDNA of dihydrolipoamide acyltransferase
(the E2 subunit) of the human BCKADC-E2 (Gene-
Bank/EMBL Data Bank; accession number: J04723)
(pkkhE2.gck, the mature protein) was obtained from
D.T. Chuang, Texas University, TX 18. The pkkhE2.gck
plasmid vector was cut with restriction enzymes Nco I and
Eco RI, and the insert was ligated into the Nco I( 5 0-end)
and Eco RI (30-end) restriction sites of pCITE-4a(þ)
translation enhancer plasmid vector (Novagen, Madison,
WI). This construct was designated pBCKADCmat and
transformed into competent Escherichia coli DH5a cells
(Gibco BRL, Eggenstein, Germany). Recombinant clones
encoding amino acid residues 1–63 (pBCKDACXba I),
1–76 (pBCKADCAcc I), 1–144 (pBCKADCEco RV) and
1–302 (pBCKADCBgl II) were generated by digesting the
pBCKADCmat vector with Xba I and Spe I, Acc I, Eco RV
and Pme I and Bgl II, respectively. Further, two subclones
encoding amino acid residues 1–97 (pBCKADCBspHI) and
AUTOANTIBODIES AGAINST BCKADC-E2 IN PBC 175143–421 (pBCKADCEco RI) were constructed either from
pkkhE2.gck vector digested with Nco I and Bsp HI or from
the pBCKADCmat by digesting the clone with Eco RV and
Eco RI. After gel puriﬁcation, the respective insert was
subcloned into pCITE 4a (þ) using either Nco Io rEco RV
and Eco RI (Fig. 1). The identity of the plasmids was
controlled by sequencing using the dideoxy sequencing
method according to the manufacturer’s speciﬁcations
(Sanger et al., 1990).
In Vitro Transcription/In Vitro Translation
of the
35S-labeled BCKADC-E2 Products
In vitro transcription and in vitro translation of 2mgo f
pBCKADCmat and its subclones were performed by the
TNT T7 Quick Coupled Transcription/Translation System
from rabbit reticulocyte lysate (Promega, Madison, WI) in
a volume of 50mla t3 0 8C for 90min in the presence
of 2mCi/mlo f(
35S)-methionine (Amersham, UK).
The amount of (
35S)-labeled BCKADC-E2 and its
truncated fragments was quantiﬁed after SDS-PAGE
using a Fuji Bas 1000 bioimaging analyzer system
(Raytest, Straubenhardt, Germany).
Radioimmunoprecipitation Assay
For quantitative antibody assay, 50,000cpm of the pooled
(
35S)-methionine-labeled protein was incubated over night
at 48C with 1ml of serum tested in a total volume of 50ml
WP0 buffer (20mM Tris–HCl (pH 7.4), 150mM NaCl,
0.5% Tween 20) on a rotating platform. Antibody-bound
labeled protein was isolated with 1mg protein A
(Afﬁ-Prep A, Bio-Rad Lab, Hercules, CA) (Hjelm et al.,
1975). After incubation for 30min at 48C a total of 75ml
immunoprecipitation mixture was washed two times with
750ml of WP1 buffer (20mM Tris–HCl (pH 7.4),
150mM NaCl, 0.5% Tween 20, 0.1% BSA). The last wash
step was performed with WP2 buffer (50mM Tris–HCl
(pH 6.8), 0.1% Tween 20). Immune complexes captured
by protein A were boiled for 5min in SDS-sample buffer.
Undissolved components were removed by centrifugation.
Ten microliters from supernatant was diluted in 1ml
scintillation ﬂuid (Optiphase Supermix, Wallac, Turku,
Finland), and the amount of radiolabeled protein was
determined with a 1450 Micro Beta Tailux Counter
(Wallac, Turku, Finland). Twenty sera recognizing both
N- and C-terminal sequences of the enzyme were titered to
the end dilution. Each serum was assayed in duplicate in
separate experiments, and the binding of different
BCKADC-E2 protein fragments was reported as the
mean of two assays. A mean interassay difference was
between 13% and 19%.
RESULTS
Patients and Sera
Of the 96 IF-AMA-positive sera evaluated by WB and
ELISA, 15 reacted only with PDC-E2 and 81 recognized
BCKADC-E2 which were used to map autoepitopes to
human BCKADC-E2. Of those 81 sera, 26 were
immunoreactive only with BCKADC-E2 and 55 sera
had autoantibodies to both BCKADC-E2 and PDC-E2.
Of the 81 patients, 68 met diagnostic criteria sufﬁcient
FIGURE 1 Subclones of the complete cDNA encoding the human BCKADC-E2 and its truncated fragments.
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of PBC. Twelve PBC sera were obtained from patients
that had undergone orthotopic liver transplantation (OLT).
The median post-OLT time was 5.2 years (range 1–12
years). Two patients developed the deﬁned criteria of PBC
after a 6-month course of interferon alfa2a therapy. The
IF analysis of PBC sera revealed 32/68 (47%) ANA
positive cases. Patterns evaluated on HEp2 cells included
multiple nuclear dots (n ¼ 13), speckled (n ¼ 10),
centromere (n ¼ 5), rim-like (n ¼ 3) and nucleolar
(n ¼ 1) features. Antibodies against smooth-muscle cells
(SMA) were detected in three sera. Seven of 81 patients
met diagnostic criteria of an “PBC-AIH overlap”
syndrome. ANA positivity was observed in six cases and
one serum had SMA reactivity. Of the 81 evaluated cases
ﬁve did not have enough available data to make a deﬁnite
diagnosis (Table I).
Sensitivity and Speciﬁcity of the Anti-BCKADC-E2
Radioligand Assay
Our radioimmunoassay was established and found
capable of measuring autoantibodies reactive with
the BCKADC-E2 target autoantigen. The RLA is so far
the ﬁrst assay utilizing human recombinant (
35S)-labeled
BCKADC-E2 protein which was produced by in vitro
transcription/invitro translation. Eighty of 81 sera positive
for BCKADC-E2 by WB and ELISA were reactive with
the human BCKADC-E2. Figure 2 shows that the
identiﬁed positive sera were above the cut-off value of
612cpm (the median value of 30 healthy control samples
plus 3SD). The mean value of the BCKADC-E2 positive
sera was 8176cpm (range 644–34,580cpm). Of the
IF-AMA- and BCKADC-E2-positive sera only one gave a
weak reactivity with the mature protein (value 644cpm).
There was no difference among sera recognizing
only BCKADC-E2 and those with reactivity toward both
PDC-E2 and BCKADC-E2.
None of sera from patients with PSC or rheumatoid
arthritis reacted with the human BCKADC-E2. Of the
AIH sera two showed a slightly elevated immunoreactivity
above the cut-off level (666 and 626cpm, respectively).
Both of them were IF-AMA-negative and there was no
evidence of bile duct involvement. No serum recognizing
only PDC-E2 was immunoreactive with BCKADC-E2
indicating the lack of cross-reactivity between
TABLE I Immunoreactivity of sera against BCKADC-E2, N- and C-terminal sequences of the mature protein
Patients Mature N-terminal C-terminal
BCKADC-E2 (1–144aa) (143–421aa)
Controls (n=94)
Blood donors (n=30) 000
AIH (n=10) 2* 0 0
PSC (n=14) 000
Rheumatoid arthritis (n=40) 000
Anti-PDC-E2+ PBC Anti-BCKADC-E2+ (n=15) 000
Deﬁnite PBC (n=66) 66 56 44
Without OLT (n=54) 54 45 39
Post-OLT (n=12) 12 11 5
Probable PBC (n=2) 222
“PBC-AIH overlap” syndrome (n=7) 761
Undetermined case (n=5) 500
Abbreviations: BCKADC-E2, branched-chain acyltransferase; AIH, autoimmune hepatitis; PSC, primary sclerosing cholangitis; PDC-E2, dihydrolipoamide
acetyltransferase; OLT, orthotopic liver transplantation; PBC, primary biliary cirrhosis; *, borderline results.
FIGURE 2 Reactivity of BCKADC-E2 positive sera with the human BCKADC-E2 by radoimmunoprecipitation assay.
AUTOANTIBODIES AGAINST BCKADC-E2 IN PBC 177autoantibodies speciﬁc either to BCKADC-E2 or to
PDC-E2 as immune target. Based on our analysis the
sensitivity and speciﬁcity of this assay was determined to
be 99 and 98%, respectively.
Epitope Mapping Experiments
All cDNA sequences subcloned into pCITE expression
vector encoding fragments of the human BCKADC-E2
were expressed in an in vitro translation/in vitro
transcription system and visualized by 12% SDS-PAGE
and phosphoimaging analyzer (Fig. 3). The characteristics
of expressed protein products and results of epitope
mapping experiments are shown in Table II. Thirty two to
34 amino acid residues encoded by pCITE vector
sequence were added to the cDNA encoded sequences in
the vector. The discrepancy between the molecular mass
calculated from the deduced primary sequence of
BCKADC-E2 protein products and that determined by
SDS-PAGE is the result of retarded migration of the
lipoyl-bearing domain by SDS-PAGE (Bleile et al., 1981;
Guest et al., 1985).
The smallest fragment of BCKADC-E2 which was
detected by 63% of the evaluated sera required amino acid
residues 1–76. The vast majority of sera displayed
immunoreactivity toward two clones encoding either
residues 1–97 (pBCKADCBsp HI) and residues 1–302
(pBCKADCBgl II) (Table II). Nine of 81 sera recognized
only the mature protein. Of particular interest was that
47 of 80 sera displayed strong reactivity toward the
C-terminal part of BCKADC-E2 (residues 143–421)
encoded by pBCKADCEco RI. Figure 4 shows that about
two thirds of PBC sera recognized C-terminal sequences
of the immune target, and some sera showed considerable
reactivity with the C-terminal domain. Three sera
exclusively recognized the C-terminus of BCKADC-E2
and displayed no immunoreactivity toward proteins
encompassing lipoyl binding domain. N-terminal
sequences encoded by plasmid pBCKADCEco RV were
recognized by 85% of the sera.PBC sera yielded reactivity
with N-terminal sequences in 85% and with C-terminal
sequences in 68%. Eleven of 12 sera from post-OLT PBC
patients were reactive with the lipoyl binding
domain. However, the C-terminus of BCKADC-E2 was
FIGURE 3
35S-labeled invitro translation products of human BCKADC-E2 cDNA clones expressed in rabbit reticulocyte lysate and evaluated in 12%
SDS-PAGE and by bioimaging analyzer.
TABLE II Characteristics of recombinant proteins encoded by BCKADC-E2 cDNA clones and their reactivity with sera (n ¼ 80) recognizing the
branched-chain acyltransferase
Clone Amino acid residues Number of
35S-methionine Cut-off level (cpm) Reactive sera (%)
pBCKADCmat (32) þ 1–421 15 (3* þ 12) 612 100
pBCKADCXbaI (32) þ 1–67 4(3*þ 1) 285 0
pBCKADCAccI (32) þ 1–76 4(3*þ 1) 479 63
pBCKADCBspHI (32) þ 1–97 4(3*þ 1) 279 85
pBCKADCEcoRV (32) þ 1–144 5 (3* þ 2) 294 80
pBCKADCBglII (32) þ 1–302 11 (3* þ 8) 465 85
pBCKADCEcoRI (34) þ 143–421 12 (4* þ 10) 613 59
*Methionine residues encoded by pCITE plasmid vector.
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OLT. Of “PBC-AIH overlap” sera (n ¼ 7) only one
recognized C-terminal sequences on the human
BCKADC-E2. There was no difference between sera
obtained from Hungarian or German patients (Table I).
Neither the clinical course nor biochemical and histo-
logical data indicated any signiﬁcant differences between
PBC patients whose sera recognized C-terminal sequences
of BCKADC-E2 and those who did not. In our RLA,
Protein A was used to capture immunocomplexes
consisting of AMA and radioactive-labeled proteins.
Human IgG1, 2 and 4 bind strongly to Protein A, while
IgG3 and IgM isotypes do not bind to it (Guest et al.,
1985). Ninety two percent of sera tested were immuno-
reactive with the human, recombinant unlipoylated
BCKADC-E2. These data indicate no notable restriction
to the IgG3 and IgM subclasses as was reported
on AMA speciﬁc to PDC-E2 (Surh et al., 1988).
Furthermore, lipoylation of the immune target is
not essential for recognition by AMA speciﬁc to
BCKADC-E2 as reported in connection with PDC-E2
(Fussey et al., 1989).
Titer of Autoantibodies Recognizing N- and
C-terminal Sequences of BCKADC-E2
Immunoprecipitation of recombinant BCKADC-E2 pro-
tein products (mature BCKADC-E2, N-terminal domain
of 1–144aa and C-terminal sequences of 143–421aa)
was performed with various serum dilutions. Twenty PBC
sera recognizing both N- and C-terminal parts of the
protein were used for further studies. The baseline dilution
was 1:50. While at a dilution of 1:500 17 sera reacted
with the studied protein products, in a titer of 5000, 60%
(12/20) of the tested sera recognized both C- and
N-terminal sequences. At a dilution of 1:50,000 two sera
showed a weak reactivity with the C-terminal part of
BCKADC-E2, and no serum recognized N-terminal
sequences.
DISCUSSION
Antibodies in response to an antigenic stimulation are
polyclonal and they recognize multiple epitopes on
immune targets (Benjamin et al., 1984; Laver et al.,
1990). Based on molecular modeling studies of antibodies
reacting with (auto)antigens at least 90% of B cell
(auto)epitopes are believed to be conformational rather
than sequential and linear (Blundell et al., 1987).
Evidence obtained by epitope mapping of a number of
autoantigens suggests that the antibody response in
autoimmune diseases is comparable to that occurring
under conditions of infection. In contrast to T cell
autoepitopes which are represented as short linear
peptides, immunodominant epitopes for B cells are more
complex and frequently involve functionally essential
sites of the target molecules (Whittingham and
McNeilage, 1988; Galperin and Gershwin, 1996). AMA
occurring in PBC sera share several similarities with those
that are present in other autoimmune diseases such as
in systemic lupus erythematodes or in scleroderma.
However, in contrast to autoantibodies in systemic lupus
erythematodes or Sjo ¨gren’s syndrome which recognize
multiple epitopes on their immune target, it is an unusual
feature of PBC-speciﬁc AMA that only one major
conformational epitope has been reported on all target
mitochondrial enzymes which encompasses the lipoyl
binding domain (Tan, 1989).
The usual method for mapping B cell autoepitopes to
immune targets is by WB which preferentially detects
linear epitopes resulting from linear sequences
exposed by the unfolding of the protein. However, the
WB tends to destroy many antibody binding sites created
FIGURE 4 Immunoreactivity of BCKADC-E2 positive sera against C-terminal sequences of the human branched chain acyltransferase.
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important conformational epitopes may be missed when
this method is exclusively employed for epitope mapping
analyses. It is therefore possible that components
recognized by WB may be pseudoepitopes arising from
linear sequences exposed by the unfolding of the protein
during denaturation (Rowley et al., 1991). Many of the
data on autoepitopes recognized by AMA in PBC were
obtained from studies in which WB was employed for
epitope mapping.
Evidence is increasing that the radioimmunoprecipita-
tion assay using unmodiﬁed recombinant proteins allows
for the detection of high-afﬁnity autoantibodies directed
against both linear and conformational sequences of
autoantigens in addition of providing a highly sensitive
method for autoantibody quantiﬁcation. An example are
the conformational epitopes located on the proliferating
cell nuclear antigen (PCNA) which were not detectable by
WB, but by immunoprecipitation assay with a full-length
construct of the antigen (Huff et al., 1990). However, a
potential limitation of the assay, is the potential failure to
detect autoantibodies directed against post-translationally
modiﬁed epitopes (e.g. lipoylation, acetylation).
BCKADC-E2 has been implicated as an immune target
in two diseases: idiopathic dilatativ cardiomyopathy
(Ansari et al., 1994) and PBC (Fregeau et al., 1989;
James et al., 1989; Surh et al., 1989; Leung et al., 1995).
By using a full-length cDNA clone for BCKADC-E2 and
truncated mutants, the immunodominant epitope recog-
nized by sera from patients with idiopathic dilatative
cardiomyopathy was localized to amino acid residues
116–134correspondingtotheE3-bindingdomain(Fig.1),
and these sera inhibited the enzyme activity (Ansari et al.,
1994). In contrast to this ﬁnding, the epitope in PBC
appears to be dependent on the three dimensional protein
structure and to include the lipoic acid binding region
(residues 1–115). Antibody binding to the lipoyl-binding
region is not dependent on the presence of lipoic acid
(Leung et al., 1995).
Of particular interest was that only the full-length clone
(amino acid residue 1–421) was sufﬁcient to remove
all detectable BCKADC-E2 reactivity. The authors
suggested that the inner E2 core and the E3 binding
domain by themselves did not have any antibody binding
(Leung et al., 1995).
Our results indicate a novel, highly sensitive
and speciﬁc RLA using (
35S)-labeled human
branched-chain acyltransferase to detect autoantibodies
speciﬁc to BCKADC-E2. Of the sera positive for anti-
BCKADC-E2 by WB and ELISA, 99% recognized the
human mature BCKADC-E2 protein by RLA. This assay
provides a sensitive and speciﬁc tool for the quantiﬁcation
of the autoantibody response toward BCKADC-E2 in
autoimmune liver diseases. Our data conﬁrmed the
ﬁndings reported by Leung et al. (1995) that an
immunodominant epitope resided on the N-terminal part
of BCKADC-E2, and antibody binding did not require the
presence of lipoic acid. The lack of immunoreactivity of
sera against the N-terminal three-fourth of lipoyl binding
domain (residues 1–63) showed that N-terminal epitope
was conformational and additional sequences of the ﬁrst
hinge region were also required.
In addition to the previous ﬁnding this study showed a
novel, major B cell autoepitope residing on the C-terminal
domain of BCKADC-E2 which was recognized by
approximately 70% of sera from patients with PBC.
Reactivity directed against C-terminal sequences was
independent from reactivity measured in the same sera
againts lipoyl binding domain. Some sera contained AMA
to C-terminal sequences of BCKADC-E2 in higher
titer than those recognizing lipoyl binding domain.
Of particular interest was that sera derived from patients
presenting with an ”overlap” syndrome of PBC and AIH
recognized the mature BCKADC-E2 and N-terminal
epitope, but not the C-terminal sequences of the
autoantigen. A degree of heterogeneity of the immune
response to BCKADC-E2 in PBC is illustrated by our
ﬁndings that 11% of sera exclusively recognized the
mature protein, and some sera were reactive only with
C-terminal sequences.
The binding property of Protein A permits
the formation of tertiary complexes consisting of
protein A, antibody and antigen (Goding, 1978). In our
reported RLA using Protein A, 99% of sera recognized
the human, unlipoylated enzyme indicating that
BCKADC-E2-speciﬁc AMA response is not restricted to
IgM and IgG3.
In conclusion, we established an immunoprecipitation-
based detection assay using recombinant human
BCKADC-E2 protein. We identiﬁed a novel B cell
autoepitope on C-terminal part of the human branched-
chain acyltransferase. N- and C-terminal sequences
of BCKADC-E2 were recognized at comparable
frequences (85 and 68%, respectively) by PBC sera.
Our data indicate that a distinct subset of AMA
recognize sequence(s) on BCKADC-E2 which are
independent of the lipoyl binding domain. Because sera
from patients presenting features of two autoimmune liver
diseases, notably PBC and AIH, did not recognize
C-terminal sequences, the lack of immunoreactivity to the
C-terminal domain may have diagnostic importance
in distinguishing PBC patients from those with “overlap”
syndrome. Further studies are required to obtain
more relevant data to conﬁrm the clinical signiﬁcance of
this new ﬁnding.
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